Founded in March 1993, Supcon is one of China’s leading providers of automation and information technology, products and solutions. SUPCON has grown rapidly on the back of cutting-edge systems for the development of innovative technology products, and to date has delivered over 30,000 control systems to a wide range of process industries.

UNISOC, a leading fabless semiconductor company based in China. Building a foremost ecosystem is the core strategy, 5G and AI are the two main technologies, Value, Future and Service are the three orientations. 

Huizhou EVE Energy was established in 2001 and became listed on Shenzhen GEM in 2009 as the first listed enterprise with lithium battery for principle work (stock code: 300014). As a national high-tech enterprise, EVE focuses on lithium battery innovation and manufacture. After 33 years’ accumulation and 15 years’ endeavour, EVE now stands in the leading position of national lithium primary battery and takes front position worldwide in lithium thionyl chloride battery manufacture.

O-Net was founded in October 2000. It is one of the key high-tech enterprises of the China Torch Program and a national enterprise technology center. O-Net has worked its way up to one of the world's largest suppliers of optical communication devices and modules through nearly 20 years of strive. And it has taken the lead in many high-tech fields such as coating film and new materials.

Junshi Biosciences is a leading pharmaceutical company operating in discovering and developing monoclonal antibody drugs in China. Founder Jun Xiong has strong spirit of innovation; core team has established the leading position in the field of tumor immunity research and development. 

The Company has produced a robust pipeline of monoclonal antibody drugs which cover tumor, cardiovascular disease, osteoporosis, and many other fields.

InnoCare is an emerging innovative drugs platform, poised to become China’s best chemical drug company covering immunology, I-O1 and oncology with sustainable innovative culture and seasoned team from global pharmaceutical companies.
InnoCare's BTK inhibitors outperform both domestic and foreign competitors in terms of safety and patient compliance (only one dosage a day), with potential to be best-in-class and clear path to regulatory approval in China around 2020.
Its R progress in FGFR4 inhibitors ranks first in China.

Akeso is recognized as one of the leaders in China for biologics discovery using the platform model with regards to software and hardware, new drug pipeline and R&D team. The company was founded by Dr Yu Xia and Dr Baiyong Li from the Sino-US Crown-Pfizer Asia Cancer Research Center and is committed to discovering and developing innovative antibody drugs with international intellectual rights.

RemeGen was cofounded in 2008 by Mr. Weidong Wang. RemeGen is committed to the discovery development and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.

Bilibili is the largest online video platform focused on anime, comics and gaming (“ACG”) in China, deriving its revenue mainly from gaming distribution, advertising and live streaming. As of Q4 2017, its average MAU was 72 million, and 82% of its user base were Generation Z (individuals born from 1990 to 2009 in China). 

The biggest feature of Bilibili is the real-time comment function on the screen, which is called “Danmu” in China by fans. The unique video experience makes Bilibili a cultural and entertainment community with interactive sharing and secondary creation.

ByteDance is the #1 entertainment platform in China, and the fastest growing one in the world. Its portfolio apps include Jinri Toutiao, the top one news app in China, as well as three apps: Huoshan short video, Douyin (Tik Tok and Musical.ly internationally) and Xigua short video. It is a full-fledged content platform with established dominant news app with new products in becoming a dominant player in short videos, and has become a global news company via several overseas acquisitions. 
With its superior algorithmic news feed mode,big date to process and analyze and extensive amount of content on Toutiao’s platform, the company has mass DAU and longest rime spent per day behind WeChat (from 50 mins in 2015 to 76 mins in 2017).

Founded in 2010, Pop Mart has become the largest designer toy company that opening up all aspects of the industrial chain including designer cooperation, IP commercialization, toy design and production, toy quality control, retail end user operations, fans operations and maintenance, etc. and creating a completed business cycle. Leveraging the increasing competition barriers, it has monopolized upstream top artists and IP, and midstream high-quality supply chain, established large offline sales channels (more than 120 offline stores with more than 700 robots), and accumulated 2 million loyal members.

NetEase Music is the second largest music platform in China behind Tencent music, differentiated as a music discovery plus social networking platform by using UGC playlists, user comments, and personalized recommendations to form its unique community.
The platform has gathered the most Generation Z users with 42% from first-tier cities and 95% below the age of 30, who are all high-quality users with strong stickiness. It has also established a comprehensive system of incubating and promoting artists, with the largest number of independent musicians.

Established in July 2004, Bayi Space is a high-tech enterprise which is professionally engaged in display using liquid crystal materials, polymer dispersed liquid crystal (PDLC) smart film, organic electroluminescent materials (OLED) display materials and R&D, production and sale of special purpose liquid crystal materials.
Bayi Space has advanced and complete analytical instrument and production equipment used for liquid crystal material research at home and abroad, and has international advanced liquid crystal display material technology. The company has developed a variety of high-grade liquid crystal materials with leading domestic level, and has independently developed the global unique panel analysis system to analyze product defects, which also helps panel manufacturers analyze defective products in the production process and provide guidance advice.

Bayi Space has more than 70 patents of domestic and international inventions. The company's products cover all kinds of liquid crystal materials used in mobile phone, notebook and computer monitor to large-sized LCD TV, and the product performance index reaches the advanced level of international similar products.

JCET Group is the world’s leading integrated-circuit manufacturing and technology services provider, offering a full range of turnkey services that include semiconductor package integration design and characterization, R&D, wafer probe, wafer bumping, package assembly, final test and drop shipment to vendors around the world. 

Founded in 2012, DiDi Chuxing is the largest ride-hailing mobile application platform in China with 94% market share, connecting riders and drivers in over 400 cities and providing around 25M rides per day in China to over 400M registered users. The company was merged from Didi Dache and Kuaidi Dache in 2015. 

In July of 2015, Didi Chuxing was announced of its completion with total assets of $2 billion and the total financing process was accomplished within two weeks. In February of 2016, Didi Chuxing had achieved financial support of $1 billion. On May 13th, 2016, Didi Chuxing made $1 billion strategic investment in Apple Corp again.

Linklogis is a supply chain finance provider offering account receivables financing. Linklogis has signed up with large corporations for managing high-quality supply chain financial assets, including Vanke, Country Garden, etc. Financial assets are exchanged through Tianjin Financial Assets Exchange, sold on as products through financial management platform of Tencent, and credit guaranteed by China Securities Credit Investment. 

Linklogis was initiated by senior managers with profound financial and internet background , and its current shareholders include Tencent, CITIC Capital and other domestic large-scale enterprises and funds.

Indigo Technology  Co., Ltd was founded in 2000. For 20 years, Indigo has committed to the R&D and production of aqueous binder for li-ion battery. Thanks to 20 years of devotion and hard work, Indigo has established the unique structure theory and preparation technology of binder for li-ion battery, and owns a number of international and domestic invention patents.

Founded in October 2016, SeeYA Technology Corporation is a high-tech enterprise specializing in the research and development, design, production, and sale of OLEDoS displays. 

Located in Guangdong province of China, Viiyong is a manufacturing enterprise of multi-layer ceramic chip capacitor (MLCC).Viiyong’s experience in MLCC industry began in 2001 when its founder, Mr. Weirong Chen resigned CEO of Konka Group, one of China’s top 5 TV brands, and started a MLCC company in Southern China.
 Joined hands by China’s leading MLCC experts, Mr. Chen achieved big success in domestic China.

EAGTOP is a specialized in researching, developing and manufacturing passive power electronics devices. Our main products include film capacitor, laminated busbar, liquid cooling plates, composite superconducting flat heat pipe, 3D phase change heat sink, reactor, resistor, braking unit, EMC filter and so on

Phyplus is a fabless IC design company providing world-class mixed-signal integrated circuits and system-on-chips. It is dedicated to developing low-power SoCs for Internet of Things (IoT). The current product portfolio includes a family of Bluetooth Low Energy (BLE) SoCs, ZigBee SoCs and multi-standard wireless SoCs. Phyplus' cost-effective BLE solution offers the lowest power consumption and the highest level of integration.

Henlius is the leading biosimilar drug company in China. The Company was jointly established in 2009 by Fosun Pharmaceutical and a team of scientists led by Dr. Scott Liu and Dr. Jiang Weidong. The Company is committed to the development and commercialization of monoclonal antibody (mAbs) biosimilar drugs, bio-betters and novel mAbs drugs. Since its establishment, the Company has always stayed true to its core value of "Quality, Speed, Innovation", and has established an advanced platform of antibody drug R&D and industrialization, which has launched a variety of pipeline drugs. Currently, the Company has comprehensive product lines, and has completed the declaration of 11 products for 17 indications of IND, and obtained 13 clinical approval documents in total. Its key product, the rituximab biosimilar drug is expected to be launched in 2018, filing the current supply gap.

JW Therapeutics is an innovative biotechnology company focused on the latest cancer CAR-T therapy technologies. It was jointly founded in 2016 by WuXi AppTec and Juno Therapeutics. By leveraging Juno’s breakthrough technology platform and WuXi AppTec’s rich experience in the local market, JW has successfully introduced Juno’s CAR-T platform into China for the benefit of Chinese patients.

Shanghai Allist Pharmaceuticals Inc. is a pharmaceutical company which are committed to launching innovative drugs with reliable curative effects which are the best in the market.
The R&D center of Allist creates core competitiveness by developing new drugss and creating personalized treatment systems. It has made a number of applications for new drugs and patents for its invention in the field of treating major diseases such as anti-hypertension, anti-tumour, anti-diabetes and other fields.

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors.

Founded in 2013 and headquartered in Shanghai, OBiO is a biotechnology company focusing on gene and cell therapy field: serving as a contract research organization for vectorology and functional genomics studies and providing contract development and manufacturing services of IND-enabling CMC, clinical and commercial manufacturing. 

Hygeia Healthcare Group is a leading oncology-focused healthcare group in China. The company operates its own hospitals, provides third-party radiotherapy service, and manages partner hospitals. Its core business consists of 7 oncology hospitals and 3 managed hospitals in in 6 provinces in China. In addition, the company provides services to 15 hospital partners (including managed hospitals) in 9 provinces of China on its radiotherapy centers. 

Abbisko is committed to R of the first-in-class and best-in-class innovative small molecule drugs for tumors. The founder of Abbisko, Dr. XU Yaochang, once served as a senior R management member at Eli Lilly and Novartis, and has established New Drugs R Center at Hansoh Pharma, which enjoys a high status in the industry.
The Company has produced a robust pipeline of inhibitors which cover liver cancer, multiple solid tumors, and many other fields.

Founded in 2017, Zhaoke Ophthalmology (SEHK: 6622) is a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs in the world. 

AIM Vaccine is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from R&D, manufacturing and commercialization. AIM Vaccine is in possession of 5 authenticated platform technologies on human vaccine. 

Bioheart is a leading interventional cardiovascular device company in China. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.

Founded in 2016 and headquarter in Palo Alto, California, Immune-Onc is a biopharmaceutical company dedicated to the development of innovative tumour antibody drugs for cancer. The company combines cutting-edge international research results with professional drug development capabilities to accelerate the progress of tumor immunotherapy drugs and bring new treatment options to cancer patients.

Suzhou Innomed Medical Device Co., Ltd. (Innomed) is an innovative technology enterprise engaged in the development and manufacturing of interventional and implantable medical devices. The company was established in January, 2013 with headquarter located in Suzhou.

Infinovo was formed in 2016. For the past several years, Infinovo has been focusing on developing an accurate and affordable CGM (Continuous Glucose Monitoring) for patients which will be available for both Type 1 and Type 2 Diabeties. The company has developed a CGM which can compete in the global market for accuracy, durability, and design.

Sciwind is a fast-growing clinical-stage biopharmaceutical company developing a portfolio of therapeutic candidates for metabolic disease. 

Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. 

Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China and Boston, USA.

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies.

Abogen is a clinical-stage biotechnology company advancing mRNA-based therapeutics for the treatment of cancer and infectious diseases. Since its establishment in January 2019, Abogen has developed its own mRNA technology platform and proprietary delivery system which empowers the development of a series of drug product candidates.

Nanjing Leads Biolabs Co.,Ltd., is a clinical-stage R&D biotech company founded in Nanjing. The company is dedicated to researching and developing novel antibody-based therapeutics in oncology and immunological disease areas to address global unmet needs of patients. 

The Arctic Circle experiences extreme and constant sunlight for half a year, and descends into total darkness for the other half. Animals living in the Arctic have evolved over time to contend with the environment – modifying their eyes and vision to see better and live well in these drastically different light conditions.

We are a biopharmaceutical company focused on the discovery and development of therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments.

In 1998, Mr.Weili Guan and Mrs.Lianyue Wang founded the Kangning hospital, which is dedicated to providing the highest quality of care for patients with mental illness. After nearly 20 years of development, Kangning hospital has become China's largest private healthcare group with nationwide subsidiaries. With 13 individually-owned and management subsidiaries, the hospital owns over 3000 beds.

In 2011, Kangning Hospital under Ministry of Health had received the national key clinical specialist (mental health) project, won the top-class hospital qualification in 2012 and is currently the only three-grade private mental health hospital.

<pIn March 2016, the Institute of psychiatry, co-founded by Kangning hospital and Wenzhou Medical University, was established, aims at dealing with shortage of medical staff in domestic psychological and psychiatric field.

Strong brand recognition across Chinese consumers and offers a product matrix that can span across both beauty & skincare with varying price ranges. 

Happy Twist, the largest drama agency in China, was founded in 2003 and has created a large amount of popular dramas, including “Clown Loves Beauty”, “Count of Mountain Wulong”, “Dream of those Years”, etc. 

In Oct 2015, Happy Twist’s first movie, “Xialuo’s trouble” earned nearly 1.5 billion RMB box office with 20 million RMB production cost. In Oct 2016, its second movie, “Donkey water” came into existence and achieved a high reputation. With more than 20 high quality original shows (IPs owned by the company), Happy Twist had over 1,600 tour shows across China in 2016.

A leading Baijiu brand for young Chinese consumers.

Established in 2011, iDreamSky is a leading mobile game publisher in China, operating and developing a series of famous mobile games through its publishing platform and third-party channels, including Fruit Ninja, Temple Run, Subway Surfers and Changing Universe etc.

With deep understanding of IP and users, the company has established a pan-entertainment system based on the game business. Through the 4 (payment system, account system, message system, sales & marketing system) + 1 (big data) + 3 (game, advertisement, value-added) business model, the company aims to become the integrated internet service platform to connect human and entertainment.

A leading brand in the edible bird’s nest market, one of the fastest growing categories for health supplements. 

Pipilu, a company specialized in Chinese original children's literature, has created classic characters in children's literature like Pipilu, Lu Xixi, Schuck and Betta . In fairy tales, Pipilu, Lu Xixi symbolize characters with excellent quality, integrity, tenacity, simplicity and gratitude, which has become beloved figures for readers of post 70s, post 80s, post 90s and even post 00s.

Mr. Zheng Yuanjie, considered as the father of Pipilu, is a famous writer of children's literature in China. His work fairy king has been published consecutively for thirty years and has become a literary classic series. In 2011, among the ten books evaluated by the United Nations, Pipilu's General Mobilization" and "Harry Potter" have both ranked the fourth. Mr Zheng Yuanjie is also an active philanthropist promoting the cause of social welfare, once won the award of "China Charity Model Award" which was presented by former president Hu Jintao and "the Angel of Love" from China Foundation for Poverty Alleviation.